SMA OneTouch ICS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SMA OneTouch ICS

The SMA OneTouch ICS is a computerized and automated viable monitoring system that controls precise and calibrated air sampling to individual or multiple SMA Atriums.   SMA Atriums are stainless steel collection devices that direct air from the environment to impact onto a nutrient agar plate. The nutrient agar plate is then evaluated to determine the amount of viable contamination in the air sample.

The SMA OneTouch ICS maintains strict regulation of the air flow during the sample cycle.  The system will automatically alarm the operator visually and audibly if the sample is compromised, aborted or completed.  In addition, the system continuously monitors the air-flow rate while sampling and will alert the operator if the air-flow deviates from the established 1 CFM flow rate of the system.

The SMA OneTouch ICS includes a touchscreen interface that incorporates facility floor plans, which provides the operator with ability to graphically select and monitor each individual SMA Atrium and helps to eliminate sampling errors.  The operator has the ability to automatically control sampling locations either simultaneously or independently.

VAI also offers the SMA OneTouch ICS for Isolators. This configuration includes all the aforementioned benefits and provides secure sampling inside the isolator environment.

Veltek Associates, Inc.
www.sterile.com
vai@sterile.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here